Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Med Mal Infect
; 50(5): 397-400, 2020 Aug.
Article
de En
| MEDLINE
| ID: mdl-32387320
ABSTRACT
INTRODUCTION:
No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.METHOD:
We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint death and/or ICU admissions.RESULTS:
Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia 676/mm3 vs 914/mm3, P=0.037 and higher CRP level 158mg/L vs 105mg/L, P=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P=0.002).CONCLUSION:
Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Admission du patient
/
Pneumopathie virale
/
Infections à coronavirus
/
Anticorps monoclonaux humanisés
/
Unités de soins intensifs
Type d'étude:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Pays/Région comme sujet:
Europa
Langue:
En
Journal:
Med Mal Infect
Année:
2020
Type de document:
Article